Wockhardt
Biosimilar developer, India. 3 development products across 3 molecules: epoetin alfa and zeta, insulin glargine, pegfilgrastim.
First approval in the Atlas: Feb 2007, Wockhardt (INN only), insulin glargine (CDSCO)
FDAproducts approved0
EMAproducts approved0
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved3
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Epoetin alfa and zeta | Wockhardt epoetin | · | · | · | · | Feb 2023 | · |
| Insulin glargine | Wockhardt insulin glargine | · | · | · | · | Feb 2007 | · |
| Pegfilgrastim | Wockhardt pegfilgrastim | · | · | · | · | Feb 2015 | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- CDSCOFeb 2007Wockhardt (INN only), insulin glargine
- CDSCOFeb 2015Wockhardt (INN only), pegfilgrastim
- CDSCOFeb 2023Wockhardt (INN only), epoetin alfa and zeta
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.